Sudan's Vital Date Industry Struggles in War-decimated Economy

Prices have collapsed in Sudan's date industry, the latest economic sector to become a casualty of war in the northeast African country. ASHRAF SHAZLY / AFP
Prices have collapsed in Sudan's date industry, the latest economic sector to become a casualty of war in the northeast African country. ASHRAF SHAZLY / AFP
TT

Sudan's Vital Date Industry Struggles in War-decimated Economy

Prices have collapsed in Sudan's date industry, the latest economic sector to become a casualty of war in the northeast African country. ASHRAF SHAZLY / AFP
Prices have collapsed in Sudan's date industry, the latest economic sector to become a casualty of war in the northeast African country. ASHRAF SHAZLY / AFP

The lush palm groves of Karima are a long way from Sudan's battlefields, but the war's effects are all too present, leaving farmers struggling to find buyers for this year's harvest.

Prices have collapsed in the vital date industry, the latest economic sector to become a casualty of war in the northeast African country, said AFP.

Every autumn, until this September, date farmers in northern Sudan pulled their harvests down from palm trees, securing a living for months to come.

But five months into the war between Sudan's rival generals, the country's economic infrastructure has been destroyed and "buyers are scared", farmer Al-Fatih al-Badawi, 54, told AFP.
Sudan is the world's seventh-largest producer of dates, growing more than 460,000 tonnes per year, according to the United Nations Food and Agriculture Organisation.
How much of that figure will be available this year remains to be seen, but farmers in northern Sudan are lucky they could manage a harvest at all.

In Karima -- a town on the Nile River about 340 kilometers (210 miles) north of the capital Khartoum -- the groves bustle with young men climbing date palms, dropping bunches of the brown fruit, beloved by Sudanese, onto white sheets below.

Farmers who depend on the date industry face colossal challenges moving their products across the country, as do those in other agricultural sectors.
Along with insecurity, wartime fuel shortages have severely hindered the ability to transport goods.

Before the war, nearly all trade in highly centralized Sudan went through Khartoum.

But constant air strikes, artillery blasts and street battles have left the capital largely off-limits to traders, who fear for their safety or are turned back by fighters at checkpoints.

"Our main market was Khartoum", Badawi said. Without it, trade is at a standstill and the price for his crop is in freefall.

Land left fallow
In Sudan, one of the world's most underdeveloped countries, dates and other agricultural products were a foundation of the pre-war economy.

The agriculture sector employed more than 80 percent of the workforce and accounted for 35 to 40 percent of gross domestic product, according to the United Nations.

But now, in much of the country including southeastern Gedaref state, known as Sudan's breadbasket, the land has been left fallow.
Processing factories have been razed or looted.

Smallholder farmers have no access to financing, traders have no guarantees of viable markets and industry heavyweights have given up.

In May, Haggar Group -- one of the agriculture sector's largest employers -- suspended operations and laid off thousands of laborers.

Even before the war began, one in three people were in need of humanitarian aid and the country's farmers -- unable to meet domestic food security needs -- struggled to break even.

The date sector in Karima had been in urgent need of "guidance and agricultural policy", as well as resources to reduce high rates of waste, said Al-Jarah Ahmed Ali, 45, another farmer.

Now the challenges have only worsened.

Since April 15, fighting between army chief Abdel Fattah al-Burhan and his former deputy, Mohamed Hamdan Daglo, commander of the paramilitary Rapid Support Forces, has torn Sudan apart.

Fighting has killed nearly 7,500 people, according to a conservative estimate from the Armed Conflict Location & Event Data Project.

More than 4.2 million people -- most of them from the Khartoum area -- have been displaced within Sudan, and another 1.1 million have fled the country, according to the International Organization for Migration.

Agricultural workers are among those joining the exodus, and while they may find relative safety in northern Sudan, whether they can earn enough to survive in a collapsing date market is questionable.

Among them is Hozaifa Youssef, a 26-year-old radiologist who left Khartoum to rejoin his family in Karima, where he is helping with the date harvest.

"I was going to India to get my master's degree," but that goal is now on hold, Youssef said.

The veteran farmer, Badawi, has not lost hope.

"We're trying to find new markets, even though it's going to be more expensive. Hopefully, the price will adjust and it will all work out."



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”